Oxford COVID-19 clinical trial aims for a viable vaccine by September


A team at Britain's Oxford University is starting human trials on a potential COVID-19 vaccine on Thursday, Health Minister Matt Hancock announced Tuesday, and the British government is "going to back them to the hilt," starting with a $25 million government investment.
Oxford's Jenner Institute and the Oxford Vaccine Group are conducting the trial. Adrian Hill, director of Jenner Institute, said last week the "aim is to have about a million doses by September once we have the results of our vaccine efficacy tests," and "then we'll move even faster from there, because it's pretty clear that the world is going to need hundreds of millions of doses ideally by the end of the year to end this pandemic." The Oxford team is trialing an experimental recombinant viral vector vaccine called "ChAdOx1 nCoV-19," one of at least 70 vaccine candidates under development worldwide, though only four have been cleared for human testing.
Prof. Sarah Gilbert, who is leading the study, said her team was already working on coronavirus vaccines last year in preparation for an outbreak of "Disease X," so once the disease hit, they were able to work "unusually quickly." Infectious disease experts warn that a vaccine won't be available for 12 to 18 months, if ever, but while "we can never be certain that these vaccines will work," Gilbert said, "personally I think it has a very strong chance of working."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
If a vaccine has been deemed safe and effective, the world will need billions of doses, and Bill Gates is among those urging the world to prepare facilities to mass-produce whatever kind of vaccine emerges victorious. That will entail global cooperation, and the Oxford team says it will produce its initial million does at plants in Britain, Europe, India, and China. The U.S. doesn't have the capacity to make the 300 million-plus doses it will need, but the U.S. government could prepare by taking over liquor or beer plants and sterilizing their fermentation vats, medical historian Arthur Silverstein tells The New York Times. "Any distillery could be converted."
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
US to take 15% cut of AI chip sales to China
Speed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with Disney
Speed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
-
Samsung to make Tesla chips in $16.5B deal
Speed Read Tesla has signed a deal to get its next-generation chips from Samsung
-
FCC greenlights $8B Paramount-Skydance merger
Speed Read The Federal Communications Commission will allow Paramount to merge with the Hollywood studio Skydance
-
Tesla reports plummeting profits
Speed Read The company may soon face more problems with the expiration of federal electric vehicle tax credits
-
Dollar faces historic slump as stocks hit new high
Speed Read While stocks have recovered post-Trump tariffs, the dollar has weakened more than 10% this year
-
Economists fear US inflation data less reliable
speed read The Labor Department is collecting less data for its consumer price index due to staffing shortages
-
Crypto firm Coinbase hacked, faces SEC scrutiny
Speed Read The Securities and Exchange Commission has also been investigating whether Coinbase misstated its user numbers in past disclosures